NCT05871398View on ClinicalTrials.gov

The Efficacy of Potassium-competitive Acid Blocker in Patients With Laryngopharyngeal Reflux Disease

PHASE3CompletedINTERVENTIONAL
Enrollment

36

Participants

Timeline

Start Date

October 1, 2019

Primary Completion Date

December 30, 2021

Study Completion Date

February 28, 2023

Conditions
Laryngopharyngeal Reflux Disease
Interventions
DRUG

Tegoprazan

Novel, potent, and highly selective potassium-competitive acid blocker which was developed in Korea

DRUG

Placebo

Placebo

Trial Locations (1)

49241

Pusan National University Hospital, Pusan

All Listed Sponsors
lead

Pusan National University Hospital

OTHER

NCT05871398 - The Efficacy of Potassium-competitive Acid Blocker in Patients With Laryngopharyngeal Reflux Disease | Biotech Hunter | Biotech Hunter